Related Experiment Video

Updated: Jul 3, 2026

Functional Characterization of Endogenously Expressed Human RYR1 Variants
07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis

Masaharu Takamori1

  • 1Neurological Center, Kanazawa-Nishi Hospital, 6-15-41, Ekinishi-Honmachi, Kanazawa, Ishikawa-ken, 920-0025, Japan. t-kiyomi@guitar.ocn.ne.jp

Journal of Neuroimmunology
|July 8, 2008
PubMed

Insights

Antibodies against transient receptor potential canonical type-3 (TRPC3) and ryanodine receptor-1 (RyR1) were found in generalized myasthenia gravis (MG) patients. These antibodies may contribute to muscle contraction abnormalities in severe MG.

Area of Science:

  • Muscle physiology
  • Immunology
  • Neuromuscular disorders

Background:

  • Transient receptor potential canonical type-3 (TRPC3) channels are involved in skeletal muscle contraction.
  • TRPC3 channels interact with ryanodine receptor-1 (RyR1) independently of sarcoplasmic calcium levels.
  • Myasthenia gravis (MG) is a neuromuscular disorder characterized by muscle weakness.

Purpose of the Study:

  • To investigate the presence of antibodies against TRPC3 and RyR1 in patients with generalized myasthenia gravis.
  • To determine if these antibodies correlate with disease severity or thymoma presence.

Main Methods:

  • Sera from 25 generalized myasthenia gravis patients were analyzed for antibodies against TRPC3 and RyR1 peptides.
  • Patient data included thymus status (thymoma or hyperplasia) and disease severity.

Main Results:

  • Antibodies against TRPC3 peptides were detected in 9 out of 25 MG patients (36%).
  • Antibodies against RyR1 peptides were found in 16 out of 25 MG patients (64%).
  • Both antibody types were more prevalent in patients with more severe myasthenia and were associated with thymoma.

Conclusions:

  • Autoantibodies against TRPC3 and RyR1 are present in a significant proportion of generalized myasthenia gravis patients.
  • These antibodies may play a role in the pathogenesis of muscle contractile dysfunction in MG, particularly in severe cases.
  • The findings suggest a potential link between TRPC3/RyR1 autoimmunity and thymoma-associated myasthenia gravis.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...